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Abstract
Sleep disturbances are prevalent in mucopolysaccharidosis Type III (MPS III), yet there is a lack of objective, ecologically valid
evidence detailing sleep quantity, quality or circadian system. Eight children with MPS III and eight age-matched typically
developing children wore an actigraph for 7–10 days/nights. Saliva samples were collected at three time-points on two
separate days, to permit analysis of endogenous melatonin levels. Parents completed a sleep questionnaire and a daily sleep
diary. Actigraphic data revealed that children with MPS III had significantly longer sleep onset latencies and greater daytime
sleep compared to controls, but night-time sleep duration did not differ between groups. In the MPS III group, sleep
efficiency declined, and sleep onset latency increased, with age. Questionnaire responses showed that MPS III patients had
significantly more sleep difficulties in all domains compared to controls. Melatonin concentrations showed an alteration in
the circadian system in MPS III, which suggests that treatment for sleep problems should attempt to synchronise the sleep-
wake cycle to a more regular pattern. Actigraphy was tolerated by children and this monitoring device can be
recommended as a measure of treatment success in research and clinical practice.
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Introduction
Mucopolysaccharidosis type III (MPS III/Sanfilippo syndrome)
is an inherited metabolic disorder characterised by an absence/
defect of lysosomal enzymes needed to break down glycosamino-
glycans (GAGs). Accumulation of GAGs leads to progressive
dysfunction of cells, tissues and organs [1], [2]. Incidence varies
across countries with 1.21 per 100,000 babies affected in the UK
[1]. MPS III has three phases [3], with the first phase (1–4 years)
characterised by developmental delay, the second phase (4–10
years) by behavioural disturbance, including sleep difficulties,
aggressive or destructive behaviours, hyperactivity and attention
difficulties, and the third/end phase (10+ years) by progressive loss
of skills (especially language), seizures, and problems with mobility
and swallowing. The four sub-types of MPS III A-D correspond to
variations in enzyme deficiency, with A and B being the most
common and D the most rare. There is little clinical difference
between subtypes [3], but A might show a more severe course [4]
and C a more attenuated course [5].
Sleep difficulties are prevalent in MPS III, particularly settling
problems, night-time waking and early morning waking [6]. Both
pharmacological and behavioural approaches have been used and
although some improvement has been reported, most treatment
has been unsuccessful. To date, there are a small number of papers
on sleep in MPS III. In four studies using parental questionnaires,
between 67–91.5% of MPS III patients exhibited sleep disturbance
[7–10], including settling difficulties, night-time waking, staying
awake all night, crying out, wandering around the house at night,
getting into parents’ bed, laughing and singing at night [7], [8].
Colville et al. [8] reported that children with MPS IIIB showed
higher rates of early morning waking and night waking compared
to sub-type A. The average age of onset of sleep problems was 3.8
years and caregivers noted an association between night-time sleep
disturbance and daytime sleepiness or aggressive behaviours [10].
Although no medications were unanimously judged to be effective,
melatonin was viewed as the most helpful [10] and 50% of
behavioural interventions resulted in meaningful improvements
[10], [8]. Clinicians reported 80–95% of MPS III patients
experienced sleep difficulties and daytime behaviours were worse
when sleep difficulties were more severe, however some reported
that behaviour actually improved when sleep was disturbed [11].
Objective measurement of sleep can be achieved by the use of
polysomnography (PSG) and actigraphy. Mariotti et al. [12]
utilised PSG with six individuals with MPS IIIA aged 7–20 years
(mean 14.1 years). Compared to age- and sex-matched controls,
MPS III patients displayed less nocturnal sleep (240.5 min vs.
458.3 min), REM sleep (8.03% vs. 21.53%) and slow wave sleep
(10.18% vs. 24.63%), but greater daytime sleep (88.8 min vs.
24.8 min). The youngest two patients (aged 7 & 9 years) slept
mainly at night but displayed nocturnal waking, whereas children
aged 12+ years showed very fragmented sleep of variable duration
across night and day. Actigraphy detects body movement to
distinguish between wakefulness and sleep. Actigraphy is more
precise than sleep diaries [13], correlates highly with PSG [14], is
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less expensive and less intrusive than PSG, and can be used to
gather with naturalistic sleep data over a long period.
It is proposed that there are abnormalities in the circadian
rhythm of melatonin concentration in specific developmental
disorders, for example an inversion of the circadian rhythm of
melatonin has been demonstrated in Smith-Magenis syndrome
[15], [16]. Given the presence of irregularly distributed sleep,
which appears to be dispersed over day and night in individuals
with MPS III, it has been suggested that there is an abnormality of
the circadian rhythm of melatonin in this disorder. Guerrero,
Pozo, Diaz-Rodriguez, Martinez-Cruz, and Vela-Campos [17]
compared twelve patients with MPS III and nine controls aged 6–
14 years over a 24-hour period. Compared to the control group,
MPS III patients had lower levels of melatonin at night and higher
levels during the day. In a mouse model study [18], MPS IIIB
mice had higher levels of activity during the resting phase, a
reduced resting phase and lower amplitude rhythm compared to
age-matched control mice. These findings support the concept of
circadian system dysfunction in MPS III, which could in turn act
as an important biomarker and clinical outcome measure [19],
[20].
The primary aim of the present study was to gather objective,
ecologically valid information on sleep and circadian rhythms in
children with MPS III. It was hypothesised that MPS III patients
would show greater settling difficulties, reduced night-time sleep,
poorer quality sleep, increased daytime sleep and an alteration of
the circadian system, compared to controls. A secondary aim was
to determine the suitability of actigraphy with this patient group
and the potential use of actigraphy as a clinical outcome measure.
No previous investigations have used actigraphy or salivary
melatonin analyses in MPS III and none have combined sleep
questionnaires with actigraphy and melatonin testing to examine
sleep and circadian alterations in MPS III patients.
Methods
Ethics Statement
National Research Ethics Service: North West 12 Research
Ethics Committee, Lancaster (REC reference number: 11/NW/
0068) approved the study.
Participants
Eight children with MPS III (5 males, 3 females; mean age 9
years 3 months, SD 4.86, age range 2–15 years) were enrolled
through their physicians at the Willink Biochemical Genetics Unit
or through the MPS Society UK. Children were selected based on
their diagnosis rather than the presence of sleep disturbance, and
diagnosis was confirmed by analysis of urine GAGs and specific
enzyme analysis. Patients who were involved in a drug study, had a
bone marrow transplant, a serious disease affecting another organ,
or were near the end of life as advised by their doctor were
excluded from this study. Demographic details are displayed in
Table 1. Two MPS III participants had epilepsy, and parents of
one of these children noted that a lack of sleep at night triggered
seizures. The younger patients were not taking any medications,
whereas the older patients were prescribed drugs for sleep (e.g.
melatonin, chloral hydrate, zopiclone), epilepsy (e.g. sodium
valproate), and other symptoms, such as pain. Only one patient
was currently prescribed melatonin, but as exogenous melatonin
impacts circadian rhythms [21], it was ceased two weeks prior to
data collection. This ensured that no lingering effects of melatonin
masked the circadian behaviour or the physiologic levels of
melatonin in saliva samples. No other medications were altered. A
group of age-matched controls (4 males, 4 females; mean age 8
years 7 months, SD 4.85, age range 3–15 years) were selected who
did not have a developmental disability, psychiatric disorder,
neurological disorder/brain injury or sleep disorder and none
were taking medication.
Table 1. MPS III Participant Information.
Sex Age Ethnicity MPS III subtype
Current intervention
(effectivenessa)
Previous treatment
for sleep problems
(effectivenessa)
Male 2 Pakistani B None None
Male 4 White Polish A None None
Male 5 White British B None Behavioural advice
(parents already
used the techniques)
Male 10 Pakistani B Melatoninb (good for settling),
Loperamide
Herbal medicine
(not effective after
the first week)
Female 10 Pakistani B Walking (seems to help)
Risperidone (not very helpful)
None
Female 11 White British A Gonapeptyl None
Male 14 White British A Chloral hydrate, Zopiclone
(both effective in the short-term,
not long-term), Levetiracetam,
Ibuprofen, Hyoscine
Melatonin (effective
in the short-term, not long-
term), Behavioural
modification (not effective)
Female 15 White British A Zopiclone, Clonazepam,
Midazolam, Sodium Valproate,
Senokot, Movicol, Omeprazole,
Glycopyrrolate, Morphine, Paracetamol
Melatonin (no effect),
Temazepam (effective
initially but became tearful & distressed)
aEffectiveness of treatment as evaluated by parents.
bMelatonin was withdrawn for the study.
doi:10.1371/journal.pone.0084128.t001
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Oral and written informed consent was obtained from a parent
of each child. Typically developing children aged six to thirteen
years also gave their assent (oral and written), and those aged
fourteen to fifteen years provided consent (oral and written). All
children received a gift voucher for taking part.
Materials and Procedure
A letter outlining the project was sent to all families with a child
with MPS III who were under the care of the Willink Unit or
known to the MPS Society UK. Children of colleagues at the
University of Manchester or a local NHS Trust formed the control
group. Participant information sheets were provided to families
who expressed an interest in taking part. A researcher met with
each family and the child’s demographic details were gathered.
Parents completed the Children’s Sleep Habits Rating Scale (E.
Shapiro, personal communication, September 6, 2010), a checklist
adapted from the Children’s Sleep Habits Questionnaire [22] to
assess sleep problems in patients with MPS III. The checklist
required parents to indicate how often each sleep behaviour
occurred in a typical week. Items were rated on a three-point scale:
‘usually’ for behaviours occurring five to seven times per week,
‘sometimes’ for those happening two to four times per week, and
‘rarely/never’ for behaviours shown up to once per week.
All children wore an actigraph (Respironics Actiwatch 2/
Cambridge Neurotechnology AW4) on their non-dominant wrist
for seven to ten days and nights, whilst carrying out their usual
activities. A 15 second sampling interval was employed. Previous
research found that a minimum of five nights data are needed to
provide meaningful actigraphic recordings of a child’s sleep, and
actigraphic monitoring should cover at least seven nights to
compensate for factors such as illness, technical problems and non-
compliance [23]. Recording for a minimum of a week meant that
data could be gathered over school days and over the weekend, as
well as allowing for potential loss of data. The sleep parameters of
interest were sleep onset latency (time between ‘lights out’ and
sleep onset), total night-time sleep duration, sleep efficiency
(percentage of time asleep between time of ‘lights out’ and ‘get
up’), wake after sleep onset (WASO, total number of minutes
awake between sleep onset and time of final waking), time in bed
(minutes) and total daytime sleep duration (total number of
minutes asleep between time of final waking and bed time). To
avoid confounding effects of large seasonal variation in circadian
rhythms, data was gathered within a six-month period and during
school term time to ensure comparability across subjects.
Caregivers noted their child’s bed times, get up times, lights on/
off times and any night-time events in a daily diary.
To allow examination of endogenous melatonin levels, parents
took saliva samples from their child at three time points (between
6–8 h, 10–12 h, & 22–24 h), on the first and last day of
actigraphic recording. Samples were collected using a suction
catheter (de Lee suction catheter; Argyle, Sherwood Medical,
Tullamore, Ireland) and were frozen at 220uC until analysis.
Night collection was performed under dim light conditions.
Samples were collected in accordance with procedures outlined
by the enzyme-linked immunosorbent assays (ELISA) kit manu-
facturer (www.IBL-International.com), to allow testing using Non-
Extraction Melatonin Saliva ELISA (IBL, Hamburg, Germany).
Preliminary analyses indicated that the data were reliable as
standard deviations were less than 20% of the mean. One outlier
was removed. Some saliva samples were missing or incomplete
and were excluded (pairwise), but 88.5% of saliva samples were
useable.
Analysis
Actigraphic data were transferred to Actiware version 5.5
software (Respironics). Rest intervals were set based on diary
information and review of the actogram (where activity and light
intensity decreased). Actigraphic and questionnaire data were
entered onto SPSS version 19 for analysis. One night’s actigraphy
data had to be excluded from the analysis for several participants
due to illness or non-compliance, but a minimum of seven nights’
data were available for all subjects. An alpha level of 0.05 was used
for all statistical tests.
Results
Children’s Sleep Habits Rating Scale
The average age of onset of sleep problems for MPS III patients
was 2 years (SD 2.33, range birth-7 years). Sleep problems
identified by parents included difficulties settling, waking up
during the night, early morning wakening, and sleeping too little.
Most children (62.5%) needed a parent in the room whilst trying
to sleep. Half of the children fell asleep within twenty minutes on
some nights, but 37.5% rarely or never did. Most parents believed
their child slept too little on at least two nights each week, but on
other nights they seemed to sleep the right amount. The majority
of children woke up once (62.5%), or multiple times (87.5%) at
night. Most of the children (75%) displayed disruptive behaviour
at night (e.g. screaming, singing, laughing), and 25% of children
displayed dangerous behaviours (e.g. running outside, playing with
appliances). All children were restless and moved a lot at night and
50% of children slept during the day.
Mann Whitney U tests demonstrated that the MPS III group
had significantly more disturbed sleep in all areas assessed by the
Children’s Sleep Habits Rating Scale. Results are displayed in
Table 2.
Actigraphy
As suggested by Acebo et al. [23], actigraphic data for each
participant were averaged over the recording period prior to
analysis. Actigraphic data for each MPS III patient can be seen in
Table 3. Night-time sleep is diminished in some patients,
particularly P8 who only slept for an average of 190 minutes per
night, however most children slept a normal amount at night. Five
out of eight children slept during the day on occasions during
actigraphic monitoring, but most children did not nap every day.
Sleep onset latency was markedly high in the majority of children.
One of the youngest children settled very quickly, within
approximately 6 minutes, but the eldest two children had distinctly
long sleep onset latencies of approximately 1 hour 10 minutes and
3 hours respectively. The remaining five children took between 25
minutes and 40 minutes to enter a sleep state. Sleep efficiency was
diminished in some children, with the eldest child sleeping only
28% of the time in bed and the five year old sleeping just 59% of
the time in bed. WASO was elevated in all children, notably the
oldest two subjects, and it ranged from 64 minutes to 207 minutes
per night across participants.
Actigraphic data from the groups were analysed using Mann-
Whitney U tests and results are displayed in Table 4. Sleep onset
latency was significantly longer in children with MPS III
compared to the control group. Night-time sleep duration and
time in bed did not differ significantly between the groups. WASO
was higher in the MPS III group, but it was not significantly
different from the control group. Although sleep efficiency was
lower in the patient group compared to controls, it did not reach
statistical significance. Daytime sleep duration was significantly
Sleep in MPS III
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longer in MPS III participants than controls. Group means can be
seen in Figure 1.
In the MPS III group, Spearman’s rank correlation coefficients
revealed a positive correlation between age and sleep onset
latency, rs=0.755, n = 8, p = 0.031, and a negative correlation
between age and sleep efficiency, rs=20.719, n = 8, p = 0.045. Age
was not significantly correlated with any other variables.
Melatonin Analyses
Melatonin levels by day and time of collection are shown in
Table 5 and the groups are compared in Figure 2. To determine
whether melatonin concentrations were influenced by day of
collection (first day vs. last day), Wilcoxon signed-rank tests were
conducted on patient and control group data, which revealed no
significant effects of day (p.0.05). A Friedman test indicated that
there was a statistically significant difference in melatonin
concentrations for the control group across time points (Time
1:6–8 h, Time 2:10 h-12 h, Time 3:22–24 h) on the first day,
x2(2) = 10.33, p = 0.002, and last day, x2(2) = 9.33, p = 0.006. Post
hoc Wilcoxon tests with Bonferroni correction (adjusted alpha
level of 0.016) showed a significant difference between Time 2 and
Time 3 on both days (p=0.016, r = 0.61), but the difference
between Time 1 and Time 3 was just above significance (p = 0.031,
r=0.59). There were no reliable differences across time points for
the MPS III group on the first day x2(2) = 0.50, p = 0.931, or last
day x2(2) = 2.80, p = 0.367. Visual inspection of the data suggested
that the MPS III group had higher melatonin concentrations at 6–
8 h and lower levels at 22–24 h, compared to controls, however
Mann-Whitney tests found no significant differences between
groups.
Discussion
Children with MPS III took longer to fall asleep and slept more
during the day compared to age-matched typically developing
children, thus supporting the initial hypotheses. There were trends
towards diminished sleep efficiency and increased nocturnal
wakefulness in the patient group. Night-time sleep duration was
not depleted in the patient group which contradicted the
hypothesis. As predicted, responses on the Children’s Sleep Habits
Rating Scale revealed that parents of children with MPS III
reported greater sleep disturbance in all domains, compared to
Table 2. Comparison of MPS III and Control Group Data on the Children’s Sleep Habits Rating Scale.
MPS III Controls
(n =8) (n=8)
Subscale Mean Median Mean Median U z r p
(SD) (IQR) (SD) (IQR)
Bedtime resistance 9.5 (2.1) 9.5 (5) 6.3 (0.5) 6.0 (1) 62.0 23.3 0.8 0.001**
Sleep onset delay 2.3 (0.7) 2.0 (1) 1.1 (0.4) 1.0 (0) 57.5 22.9 0.7 0.006**
Sleep duration 6.1 (1.6) 6.0 (1) 3.0 (0) 3.0 (0) 60.0 23.3 0.8 0.001**
Sleep anxiety 6.4 (2.7) 5.5 (4) 4.0 (0) 4.0 (0) 56.0 22.9 0.7 0.007**
Night wakings 5.9 (1.5) 6.5 (2) 3.9 (1) 3.5 (2) 55.0 22.5 0.6 0.016*
Night behaviours 3.3 (1.3) 3.0 (2) 2.0 (0) 2.0 (0) 56.0 22.9 0.7 0.007**
Parasomnias 9.8 (1.7) 9.0 (4) 6.4 (0.7) 6.0 (1) 63.0 23.3 0.8 0.000**
Sleep disordered breathing 4.8 (1.8) 4.0 (3) 3.0 (0) 3.0 (0) 56.0 22.9 0.7 0.007**
Daytime sleepiness 16.0 (4.1) 14.5 (8) 12.3 (2.1) 12.5 (2) 51.0 22.0 0.5 0.045*
SD, standard deviation; IQR, interquartile range. Items were grouped into nine subscales. Each item was assigned a score between 1 and 3 and some items were reverse-
scored to ensure that a higher score represented poorer sleep.
*p,.05, **p,.01.
doi:10.1371/journal.pone.0084128.t002
Table 3. Sleep Parameters (per night) for MPS III Participants Averaged over the Recording Period.
Age (years)
Sleep variable P1 P2 P3 P4 P5 P6 P7 P8 Control
2 4 5 10 10 11 14 15 mean
Time in bed (min) 570.9 589.5 593.8 579.1 528.8 558.2 659.4 397.4 544.9
Night-time sleep (min) 507.2 504.5 396.6 497.3 464.9 484.0 532.8 190.2 479.0
Daytime sleep (min) 46.5 0 1.2 0 40.6 0 16.4 6.0 1.7
Sleep onset latency (min) 38.6 6.3 24.8 30.4 32.2 39.1 70.9 183.3 14.2
Sleep efficiency (%) 81.0 79.6 59.3 79.2 73.7 77.5 70.5 28.6 80.8
WASO (min) 63.7 85.0 197.2 81.8 63.9 74.2 126.6 207.2 75.1
WASO, wake after sleep onset.
doi:10.1371/journal.pone.0084128.t003
Sleep in MPS III
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e84128
parents of typically developing children. In the patient group,
increased age was associated with greater sleep onset latency and
lower sleep efficiency. As hypothesised, MPS III children showed
disruption in their circadian system.
The MPS III group took an average of 53 minutes to fall asleep
compared to the expected 20–30 minutes [24], [25]. The
prolonged sleep onset latency in MPS III suggests difficulties
initiating sleep that could relate to low night-time melatonin levels.
On average, MPS III patients slept during the day for 14 minutes,
with those in the late stage sleeping more during the day than
those in the middle phase. This was in line with previous PSG
findings [12]. It should be noted that daytime sleepiness in
children is associated with behavioural problems, depression, and
reduced quality of life [26]. With increasing age, children with
MPS III took longer to fall asleep and their sleep was less efficient.
Children normally sleep for at least 80% of their time in bed [27],
[28], but the average of the MPS III group was 68.7%. However
sleep efficiency for some children was only just below normal with
only two participants showing very poor sleep efficiency (59.3%
and 28.6% respectively). The length of time that MPS III children
were awake at night was very high, with an average of almost two
hours per night and such wakefulness was particularly noticeable
in the two oldest children.
In Mariotti and colleagues’ [12] paper night-time sleep was
reduced in MPS III. In the current study average night-time sleep
in the MPS III group was lower than controls, however it was not
significantly different. Some patients’ sleep varied from one night
to the next, and when sleep was averaged over the recording
period, children with MPS III appeared to be getting a sufficient
quantity of sleep. All Mariotti and colleagues’ [12] subjects were
MPS IIIA, whereas the current study included both A and B
subtypes. This might account for some of these differences, as
might the disparity in subjects’ ages across the two studies.
Results from the Children’s Sleep Habits Rating Scale showed
that in comparison to typically developing children, parents of
Figure 1. Mean actigraphic results of MPS III (n=8) and control groups (n=8). Error bars represent standard error of the mean. (A) Duration
of time in bed. (B) Duration of night-time sleep. (C) Duration of daytime sleep. (D) Sleep onset latency. (E) Sleep efficiency. (F) Wake after sleep onset. *
p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0084128.g001
Table 4. Comparison of Sleep Parameters in Children with
MPS III and Controls.
MPS III Controls
n =8 n=8
Sleep
parameter
Median
(IQR)
Median
(IQR) U z r p
Time in
bed (min)
575.0
(56.6)
531.6
(55.6)
44.0 21.3 0.3 0.23
Night-time
sleep (min)
490.6
(92.9)
496.2
(61.4)
32.0 0 0 1.0
Daytime
sleep (min)
3.6
(34.6)
0
(0)
48.5 22.0 0.5 0.046*
Sleep onset
latency (min)
35.4
(36.8)
14.9
(7.6)
56.0 22.5 0.6 0.01**
Sleep
efficiency (%)
75.6
(17.4)
82.8
(15.1)
17.5 21.5 0.4 1.4
WASO
(min)
83.4
(113.1)
60.4
(94.7)
43.0 21.2 0.3 0.279
WASO, wake after sleep onset; SD, standard deviation.
*p,.05, **p,.01.
doi:10.1371/journal.pone.0084128.t004
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children with MPS III saw their child as having more difficulties
with bedtime resistance, falling asleep, sleep duration, sleep
anxiety, night waking, night behaviours, parasomnias, sleep
disordered breathing and daytime sleepiness. The average age of
onset of sleep difficulties was 2 years old, but sleep disordered
breathing (snoring, snorting/gasping and apnea) can be present
from birth in some instances [29], [30], [6].
In a mouse model paper [18], comparable results to this study
were reported. MPS IIIB mice had higher levels of activity during
the resting phase, a reduced resting phase and lower amplitude
rhythm. This could explain napping during the active phase,
night-time waking and nocturnal activity.
Salivary melatonin analyses showed altered circadian rhythm of
melatonin concentration in MPS III with lower melatonin levels at
night and higher levels early morning. However these differences
were not significantly different from controls, partly due to the
small sample size and large variability within the groups.
Melatonin levels were differentiated at specific time points over
day and night in typically developing children. However in MPS
III patients, no reliable differences across time were found. In
Canal and colleagues’ [18] study, MPS IIIB mice had a lower
sensitivity to light at the behavioural (shorter phase shift after a
light pulse in the dark) and the molecular level (decreased
expression of vasointestinal polypeptide protein in the suprachi-
asmatic nucleus (SCN)). If comparable processes hold in humans
with MPS III, this could account for the abnormal melatonin
levels observed in the current study.
Given the abnormal melatonin concentrations observed in MPS
III, exogenous melatonin is likely to be the most effective
pharmacological intervention, as substantiated by previous
research [11]. The strongest evidence for the efficacy of melatonin
is for reducing sleep onset latency, but there is less support for its
effect on nocturnal waking [31]. Compared to the usual fast
release form, sustained-release melatonin can improve sleep
maintenance in children with neurodevelopmental disorders
[32], but such treatment could exacerbate daytime sleepiness,
which should be avoided in patients who already display tiredness
during the day. Moreover, melatonin should be used with caution
given concerns about its use with children, its long-term effects are
unknown [33] and there is some evidence of an increase in seizures
in children with neurodevelopmental disorders with epilepsy [34].
As with much research into very rare disorders, the current
sample size was small with limited statistical power to detect
between-group differences or disparities between subtypes or
stages of the disorder. Inspection of standard deviations revealed
the MPS group had more variability on all sleep measures
compared with controls, and sleep difficulties, particularly sleep
onset latency and sleep efficiency, worsened as the children aged
and the disease progressed.
With regard to the feasibility of actigraphy with this population,
it is inherently more accurate than diary entries and parents
reported few problems with their child tolerating the watch, which
suggests it is suitable for wider use in both clinical practice and
research with MPS III patients.
Further investigations are needed to validate the findings of this
study. With more resources, a larger sample including adults as
well as children, would substantiate these results and provide
greater clarity of sleep at different stages of the disorder. Some
parents of children with MPS III reported that occasionally their
child would not sleep at all for one night and this unpredictability
makes it difficult to plan their daily lives. Recording over a longer
time period of several weeks, would allow more variability across
nights to be captured. Rather than averaging data across nights,
time series analysis could identify patterns and allow periods of
sleeplessness to be predicted and a longitudinal study following
MPS III patients through the progression of the disorder would
document more precisely how sleep patterns change with age and/
or subtypes.
A number of promising treatments for MPS III which target the
central nervous system are currently being studied, including
enzyme replacement therapy, hematopoietic stem cell transplan-
tation, gene therapy, and substrate reduction therapy [35]. Until a
clinically efficacious treatment for MPS III has been developed, it
Figure 2. Melatonin concentrations (average 6 SEM) in MPS III patients and controls. Saliva samples were collected at the times shown
on. (A) First day of actigraphic monitoring. (B) Last day of actigraphic recording.
doi:10.1371/journal.pone.0084128.g002
Table 5. Median (IQR) Melatonin Concentrations across
Groups, Time points and Days.
Melatonin concentrations (pg/mL) by day and time
First day Last day
Group 6–8 h 10–12 h 22–24 h 6–8 h 10–12 h 22–24 h
MPS III 14 (14.1) 6.6 (8.6) 19 (20.4) 11 (10) 11.1 (10.2) 38.2 (40)
Controls 4.3 (10.8) 11.1 (29) 51.5 (87) 7.7 (9) 9 (27.8) 45.7 (87.7)
IQR, interquartile range.
doi:10.1371/journal.pone.0084128.t005
Sleep in MPS III
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remains for clinicians to target manifestations of the condition,
including sleep disturbance, to improve the quality of life of
individuals and their families.
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